According to filings with the U.S. Securities and Exchange Commission, Candid Therapeutics is raising up to $206,203,454.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Kenneth Song played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Candid Therapeutics
Clinical stage biotechnology company dedicated to advancing the treatment of a range of immunological conditions. We are driven by a singular mission: Apply known biology to create novel, easy to administer therapies that materially benefit patients with autoimmune diseases. Our team is led by industry experts with a track record of stakeholder value creation. We are pioneering a new frontier in autoimmune therapy with T-cell engager antibodies. By precisely redirecting T-cells to selectively eliminate autoreactive B-cells, we aim to achieve transformative efficacy safely. Our approach is grounded in rigorous scientific research and a deep understanding of immunological mechanisms.

To learn more about Candid Therapeutics, visit http://www.candidrx.com/
Candid Therapeutics Linkedin Page: https://www.linkedin.com/company/candidrx/

Contact:
Kenneth Song, President and Chief Executive Officer
858-247-0550
https://www.linkedin.com/in/kssong/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.